Showing results (131-140 of 194) with videos related to
Sort By:
Pageof 20
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.Journal of Clinical Microbiology|January 17, 2014
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TBAnne F Luetkemeyer, Michelle A Kendall, Xingye Wu, et al.The Journal of Antimicrobial Chemotherapy|December 25, 2019
Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adultsScott L Letendre, Anthony Mills, Debbie Hagins, et al.The American Journal of Tropical Medicine and Hygiene|August 21, 2023
Preferences of Patients and Providers in High-Burden Malaria Settings for Long-Acting Malaria ChemopreventionKimberly K Scarsi, Harlan Sayles, Kelvin Kapungu, et al.Antiviral Research|April 10, 2018
Adipocytes impair efficacy of antiretroviral therapyJacob Couturier, Lee C Winchester, James W Suliburk, et al.Contraception|October 3, 2024
Comparison of etonogestrel bioanalytical assay results in plasma and serum within and across laboratoriesShawnalyn W Sunagawa, Lee C Winchester, Christopher S Wichman, et al.Contraception|January 14, 2023
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimensKimberly K Scarsi, Laura M Smeaton, Anthony T Podany, et al.Journal of the International AIDS Society|January 9, 2020
New opportunities in tuberculosis prevention: implications for people living with HIVLucia González Fernández, Esther C Casas, Satvinder Singh, et al.JAMA|August 15, 2006
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppressionSusan Swindells, A Gregory DiRienzo, Timothy Wilkin, et al.American Journal of Respiratory and Critical Care Medicine|January 17, 2020
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical TrialKelly E Dooley, Sachiko Miyahara, Florian von Groote-Bidlingmaier, et al.Pageof 20